New CB2 agonists (HU910) for the treatment of wide range of disorders including Inflammation, Pain, Neurological and Neurodegenerative diseases, MS, Cancer

Mechoulam Raphael, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Bab Itai, HUJI, Faculty of Dental Medicine
Shohami Esther, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Magid Lital, HUJI, School of Medicine - IMRIC


  • Agonists that bind well to the cannabinoid CB2 receptor and do not bind, or only bind weakly to the cannabinoid CB1 receptor are very promising therapeutic compounds for a wide range of disorders.
  • CB1 agonists (such as the marijuana constituent THC) lead to undesirable side psychoactive effects. Therefore CB1 agonists, which act on the central nervous system, are of limited therapeutic value
  • These compounds bind specifically to the cannabinoid CB2 receptor
  • Demonstrated improvement in head injury in small animals – reduces production of PNF alpha

Our Innovation

Novel small molecule compounds that are agonists specifically to the cannabinoid CB2 receptor for the treatment of diseases associated with stimulation of CB2 receptors

Application for use:

Compounds have applications in wide range of disorders including: inflammation; pain; neurological and neurodegenerative diseases; liver diseases; cerebral injury; cancer; retinal vascularisation; endometritis; atherosclerosis, disorders related to anti-fibrinogenic effects; inflammatory bowel disease; arthritis; and in stimulation of bone growth, bone repair or prevention of bone loss in osteoporosis and bone fracture.Low-cost, specific compounds for treating a wide variety of disorders without producing side effects

Development Milestones

Seeking funding for ongoing research; licensing agreements with companies in the fields mentioned below to develop specific therapeutic compounds



Patent Status

Granted US 8,722,938; US 9,365,534; Australia 2010320467; China 201080049552.1; Europe 2501669; India 336277; Israel 218216; Israel 237753; Mexico 329271; Mexico 355972; Russian Federation 2578715

Contact for more information:

Mel Larrosa
VP Business Development Healthcare